Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer

Adds To Colorectal Cancer Opportunity

 
• By Andrew McConaghie
  
Mirati Therapeutics
Mirati is expecting its first approval for adagrasib by mid-2022 in NSCLC - but is looking to carve out a niche in CRC and GI cancers ahead of Amgen. • Source: Mirati Therapeutics

More from Business

More from Scrip